IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
35.00
-0.28 (-0.79%)
At close: Sep 20, 2024, 4:00 PM
35.39
+0.39 (1.11%)
After-hours: Sep 20, 2024, 4:28 PM EDT
IDEAYA Biosciences Employees
IDEAYA Biosciences had 124 employees as of December 31, 2023. The number of employees increased by 21 or 20.39% compared to the previous year.
Employees
124
Change (1Y)
21
Growth (1Y)
20.39%
Revenue / Employee
$96,460
Profits / Employee
-$1,239,831
Market Cap
2.96B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bausch Health Companies | 20,270 |
Concentra Group Holdings Parent | 9,020 |
QuidelOrtho | 7,100 |
Tandem Diabetes Care | 2,400 |
HUTCHMED (China) | 1,988 |
Guardant Health | 1,779 |
Iovance Biotherapeutics | 557 |
Xenon Pharmaceuticals | 259 |
IDYA News
- 2 days ago - IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel - PRNewsWire
- 21 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 25 days ago - IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co. - Business Wire
- 7 weeks ago - Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program - Business Wire
- 7 weeks ago - IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event - PRNewsWire